Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Laudani, A. [1 ]
Savio, G. [1 ]
Leonardi, V. [1 ]
Palmisano, V. [1 ]
Tartaglia, L. [1 ]
Manuguerra, G. [1 ]
Pepe, A. [1 ]
Alu, M. [1 ]
Usset, A. [1 ]
Agostara, B. [1 ]
机构：
[1] PO M Ascoli ARNAS Civico, Med Oncol Unit, Dept Oncol, Palermo, Italy
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [21] First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer
    Michalaki, V.
    Gennatas, C.
    Gennatas, S.
    Vasiliou, J.
    Smyrniotis, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer
    Park, SH
    Bang, SM
    Cho, EK
    Baek, JH
    Oh, JH
    Im, SA
    Park, YS
    Shin, DB
    Lee, JH
    ONCOLOGY, 2004, 66 (05) : 353 - 357
  • [23] Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer
    Gennatas, C.
    Michalaki, V.
    Gennatas, S.
    Papalambros, E.
    ANTICANCER RESEARCH, 2008, 28 (3B) : 1923 - 1926
  • [24] Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer
    Michalaki, V.
    ANNALS OF ONCOLOGY, 2008, 19 : I45 - I45
  • [25] Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer
    Punt, Cornelis J. A.
    Koopman, Miriam
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1907 - 1908
  • [26] A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (PTS) with advanced or metastatic colorectal cancer (MCRC)
    Maroun, Jean A.
    Jonker, Derek
    Goel, Rakesh
    Cripps, Christine
    Lister, Diane
    Chiritescu, Gabriela
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [27] Oxaliplatin and Capecitabine (CAPOX) in Non Selected Patients With Metastatic Colorectal Cancer (MCRC) After First-line Irinotecan Based Regimen
    Fonseca, P. J.
    Solis, P.
    Vieitez, J. M.
    Izquierdo, M.
    Pardo, P.
    Gutierrez, E.
    Perez, Q.
    Alvarez, C.
    Frunza, M.
    Uriol, E.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S422 - S423
  • [28] Updated phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [30] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V
    ANNALS OF ONCOLOGY, 2009, 20 : 76 - 76
12345